Alan joined Polaris Partners in 2002 and serves as an entrepreneur partner. In this role, he focuses on building and investing in healthcare companies.
He has served as founder, chairman and/or CEO in building nine Polaris companies. One of Alan’s latest ventures is Dyno Therapeutics, which he co-founded along with Harvard Professor George Church and scientist Eric Kelsic. The company is using insights from computer science and biology to design better viruses for delivery of gene therapies. Prior to Dyno, Alan founded Pandion Therapeutics to focus on tissue-specific immunomodulation for autoimmune disorders and transplantation. In four years from the Polaris seed funding, Pandion became a clinical-stage, public company and was acquired by Merck for $1.85B. Alan’s past portfolio companies have collectively been involved in 12 IPOs and M&A exits.
His current and past portfolio include: Momenta Pharmaceuticals (acquired by J&J), Visterra (acquired by Otsuka), Navitor Pharmaceuticals, Dyno Therapeutics, Pandion Therapeutics (acquired by Merck), KSQ Therapeutics, T2 Biosystems, Ocular Therapeutix, Sirtris Pharmaceuticals (acquired by GSK), Adnexus Therapeutics (acquired by BMS), Arsia Therapeutics (acquired by Eagle Pharmaceuticals), Seventh Sense Biosystems, Cerulean Pharma, and XTuit Pharmaceuticals. From 2002 to 2006, Alan was president and CEO of Momenta Pharmaceuticals. He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales. Momenta was acquired by J&J for $6.5B.
Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade®, which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.
Alan received Ernst & Young’s Entrepreneur of the Year award for New England while serving as CEO of Momenta. His current and former non-profit positions include: selection committee for the Harvard Life Lab, expert-in-residence at the Harvard School of Engineering, board member of the Boston Children’s Hospital Trust, founder and vice chair of the Autism Consortium, and president of the board of Gann Academy.
Alan earned a BA in biology, summa cum laude, from Harvard College, an MA in cellular and developmental biology from Harvard Graduate School of Arts & Sciences and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.
Alan enjoys spending his free time traveling with his wife, three sons and daughter-in-law and working with non-profits in education and healthcare.